GlaxoSmithKline - Pharma manufacturing consent decrees

Start Date: 2005
Financial penalties: $650 million bond
End Date: still pending

The subject of this consent decree was GSK's failure to meet quality standards for the diabetes medication Avandia met and antidepressant Paxil that it manufactured in Cidra, Puerto Rico.

The regulator began investigating the plant in 2002, and U.S. Marshalls raided it in 2005, seizing inventory. The bond was contingent on the drugmaker reconditioning or destroying the seized drugs. GSK ultimately closed the plant in 2009.

GlaxoSmithKline - Pharma manufacturing consent decrees
Read more on